Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Ionis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$944.00M

Latest Revenue (Q)

$156.72M

Main Segment (Y)

Commercial Member

Ionis Pharmaceuticals Revenue by Period

Ionis Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$944.00M	33.87%
2024-12-31	$705.14M	-10.48%
2023-12-31	$787.65M	34.10%
2022-12-31	$587.37M	-27.53%
2021-12-31	$810.46M	11.13%
2020-12-31	$729.26M	-35.04%
2019-12-31	$1.12B	87.20%
2018-12-31	$599.67M	16.63%
2017-12-31	$514.18M	37.93%
2016-12-31	$372.78M	31.40%
2015-12-31	$283.70M	32.47%
2014-12-31	$214.16M	45.41%
2013-12-31	$147.28M	44.33%
2012-12-31	$102.05M	2.99%
2011-12-31	$99.09M	-8.65%
2010-12-31	$108.47M	-10.80%
2009-12-31	$121.60M	13.44%
2008-12-31	$107.19M	83.72%
2007-12-31	$58.34M	292.65%
2006-12-31	$14.86M	-62.98%
2005-12-31	$40.13M	-5.84%
2004-12-31	$42.62M	-14.73%
2003-12-31	$49.99M	-37.65%
2002-12-31	$80.18M	50.51%
2001-12-31	$53.27M	43.00%
2000-12-31	$37.26M	9.90%
1999-12-31	$33.90M	-13.52%
1998-12-31	$39.20M	19.88%
1997-12-31	$32.70M	44.05%
1996-12-31	$22.70M	74.62%
1995-12-31	$13.00M	28.71%
1994-12-31	$10.10M	-16.53%
1993-12-31	$12.10M	-

Ionis Pharmaceuticals generated $944.00M in revenue during NA 2025, up 33.87% compared to the previous quarter, and up 129.45% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-10-28	$156.72M	-65.33%
2025-06-30	$452.05M	243.47%
2025-03-31	$131.61M	-41.91%
2024-12-31	$226.58M	69.09%
2024-09-30	$134.00M	-40.51%
2024-06-30	$225.25M	88.50%
2024-03-31	$119.50M	-63.18%
2023-12-31	$324.50M	125.35%
2023-09-30	$144.00M	-23.40%
2023-06-30	$188.00M	43.51%
2023-03-31	$131.00M	-13.82%
2022-12-31	$152.00M	-4.86%
2022-09-30	$159.77M	19.42%
2022-06-30	$133.79M	-5.73%
2022-03-31	$141.92M	-67.75%
2021-12-31	$440.00M	230.60%
2021-09-30	$133.09M	5.84%
2021-06-30	$125.75M	12.67%
2021-03-31	$111.61M	-61.51%
2020-12-31	$290.00M	81.16%
2020-09-30	$160.08M	9.99%
2020-06-30	$145.54M	9.13%
2020-03-31	$133.37M	-73.00%
2019-12-31	$494.00M	194.24%
2019-09-30	$167.89M	2.37%
2019-06-30	$164.00M	-44.82%
2019-03-31	$297.21M	54.71%
2018-12-31	$192.11M	32.13%
2018-09-30	$145.40M	23.48%
2018-06-30	$117.75M	-18.47%
2018-03-31	$144.42M	-16.18%
2017-12-31	$172.30M	42.50%
2017-09-30	$120.91M	16.09%
2017-06-30	$104.15M	-5.58%
2017-03-31	$110.30M	-31.21%
2016-12-31	$160.35M	44.55%
2016-09-30	$110.93M	188.35%
2016-06-30	$38.47M	4.33%
2016-03-31	$36.87M	-28.50%
2015-12-31	$51.57M	4.99%
2015-09-30	$49.12M	-59.21%
2015-06-30	$120.43M	92.43%
2015-03-31	$62.58M	-26.25%
2014-12-31	$84.86M	92.59%
2014-09-30	$44.06M	-22.80%
2014-06-30	$57.08M	102.68%
2014-03-31	$28.16M	-33.35%
2013-12-31	$42.25M	79.14%
2013-09-30	$23.59M	-38.08%
2013-06-30	$38.09M	-12.15%
2013-03-31	$43.36M	118.19%
2012-12-31	$19.87M	71.30%
2012-09-30	$11.60M	-75.49%
2012-06-30	$47.34M	103.74%
2012-03-31	$23.23M	-28.29%
2011-12-31	$32.40M	56.44%
2011-09-30	$20.71M	-16.56%
2011-06-30	$24.82M	17.38%
2011-03-31	$21.15M	-19.96%
2010-12-31	$26.42M	-7.70%
2010-09-30	$28.62M	21.79%
2010-06-30	$23.50M	-21.46%
2010-03-31	$29.93M	-7.24%
2009-12-31	$32.26M	20.51%
2009-09-30	$26.77M	-13.62%
2009-06-30	$30.99M	-1.85%
2009-03-31	$31.58M	52.83%
2008-12-31	$20.66M	-35.87%
2008-09-30	$32.22M	-2.26%
2008-06-30	$32.96M	54.36%
2008-03-31	$21.35M	-13.64%
2007-12-31	$24.73M	-

Ionis Pharmaceuticals generated $156.72M in revenue during Q3 2025, up -65.33% compared to the previous quarter, and up 69.58% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue Breakdown

Ionis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Royalty	$285.53M	-	-	-	-
Commercial Member	$435.85M	-	-	-	-
Product	$115.31M	$34.19M	$34.91M	$30.05M	-
Other Commercial	-	$56.78M	$68.21M	-	-
Other	-	$22.59M	-	-	-
Collaborative Agreement Revenue	-	$332.65M	$352.66M	$207.22M	-
Commercial	-	$293.08M	$308.59M	$303.36M	$342.39M
Research and Development Revenue	-	$412.06M	$479.06M	$284.01M	-
SPINRAZA Royalties	-	$216.09M	$240.38M	-	-
Licensing and Other Royalties	-	-	$33.30M	$30.99M	$19.12M
Eplontersen Joint Development Revenue	-	-	-	$76.79M	-
Spinraza Royalties	-	-	-	$242.31M	$267.78M
TEGSEDI and WAYLIVRA	-	-	-	-	$55.50M
Research and Development Revenue Under Collaborative Agreements	-	-	-	-	$468.06M

Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Commercial Member (52.09%), Royalty (34.13%), and Product (13.78%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23
Royalty	$75.72M	$75.69M	$69.95M	$64.17M	-	-	-	-	-	-
Commercial Member	$217.49M	$115.60M	$102.76M	-	-	-	-	-	-	-
Product	$64.25M	$31.79M	$19.27M	$17.07M	$8.92M	$8.19M	$20.15M	$8.29M	-	-
SPINRAZA Royalties	-	-	-	$48.01M	$102.14M	$57.21M	$56.74M	$112.11M	$67.25M	$61.01M
TEGSEDI and WAYLIVRA	-	-	-	$5.71M	-	-	-	-	-	-
Product Sales, Net	-	-	-	$6.29M	-	-	-	-	-	-
Other Commercial	-	-	-	$5.71M	$32.12M	$13.15M	$11.51M	$34.50M	$16.83M	$16.89M
Commercial	-	-	-	$76.17M	$145.31M	$75.73M	$72.04M	$78.84M	$84.08M	$77.90M
Collaborative Agreement Revenue	-	-	-	$45.03M	$146.24M	$44.88M	$141.52M	$179.14M	$44.17M	$91.01M
Research and Development Revenue	-	-	-	$55.44M	$200.76M	$58.08M	$153.21M	$245.66M	$60.13M	$110.51M
Licensing and Other Royalties	-	-	-	-	-	$4.23M	$3.32M	$13.71M	$8.54M	-
Eplontersen Joint Development Revenue	-	-	-	-	-	-	-	-	$15.96M	$19.50M

Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Commercial Member (60.84%), Royalty (21.18%), and Product (17.97%).

Ionis Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BMRN	BioMarin Pharmaceutical	$3.22B	$776.13M
EXEL	Exelixis	$2.32B	$597.75M
MRNA	Moderna	$1.94B	$1.02B
GH	Guardant Health	$982.02M	$265.20M
MDGL	Madrigal Pharmaceuticals	$958.40M	$287.27M
IONS	Ionis Pharmaceuticals	$944.00M	$156.72M
BBIO	BridgeBio Pharma	$362.37M	$108.11M
ASND	Ascendis Pharma	$266.72M	$95.89M
ROIV	Roivant Sciences	$124.80M	$2.00M
RVMD	Revolution Medicines	-	-
SMMT	Summit Therapeutics	-	-

IONS Revenue FAQ

What is Ionis Pharmaceuticals’s yearly revenue?

Ionis Pharmaceuticals's yearly revenue for 2025 was $944M, representing an increase of 33.87% compared to 2024. The company's yearly revenue for 2024 was $705.14M, representing a decrease of -10.48% compared to 2023. IONS's yearly revenue for 2023 was $787.65M, representing an increase of 34.10% compared to 2022.

What is Ionis Pharmaceuticals’s quarterly revenue?

Ionis Pharmaceuticals's quarterly revenue for Q3 2025 was $156.72M, a -65.33% decrease from the previous quarter (Q2 2025), and a 16.95% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $452.05M, a 243.47% increase from the previous quarter (Q1 2025), and a 100.69% increase year-over-year (Q2 2024). IONS's quarterly revenue for Q1 2025 was $131.61M, a -41.91% decrease from the previous quarter (Q4 2024), and a 10.14% increase year-over-year (Q1 2024).

What is Ionis Pharmaceuticals’s revenue growth rate?

Ionis Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 19.85%, and for the last 5 years (2021-2025) was 16.48%.

What are Ionis Pharmaceuticals’s revenue streams?

Ionis Pharmaceuticals's revenue streams in c 25 are Royalty, Commercial Member, and Product. Royalty generated $285.53M in revenue, accounting 34.13% of the company's total revenue Commercial Member generated $435.85M in revenue, accounting 52.09% of the company's total revenue Product generated $115.32M in revenue, accounting 13.78% of the company's total revenue, up 237.29% year-over-year.

What is Ionis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Ionis Pharmaceuticals was Commercial Member. This segment made a revenue of $435.85M, representing 52.09% of the company's total revenue.